Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04446377 · ClinicalTrials.gov registry record · Phase 2
A Study of LAM-002A for the Prevention of Progression of COVID-19
A Phase 2 study, sponsored by OrphAI Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT04446377 is a Phase 2 study that has completed, run by OrphAI Therapeutics. The registered enrollment target is 142 participants.
The verdict
NCT04446377, a Phase 2 study, has completed, sponsored by OrphAI Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
Interventions
- OTHER Placebo
- DRUG Apilimod Dimesylate Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2021-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04446377
The ClinicalTrials.gov registry entry for NCT04446377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OrphAI Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04446377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04446377 about?
NCT04446377 is a clinical study titled "A Study of LAM-002A for the Prevention of Progression of COVID-19". This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
What is the current status of trial NCT04446377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2020-07-15. Estimated completion is 2021-04-19.
What interventions are being tested in trial NCT04446377?
The interventions under investigation include: Placebo (OTHER), Apilimod Dimesylate Capsule (DRUG).
Who is sponsoring clinical trial NCT04446377?
This trial is sponsored by OrphAI Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.